Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sacituzumab tirumotecan with or without pembrolizumab versus physician's choice chemotherapy in first-line PD-L1 low metastatic triple-negative breast cancer
NL-OMON61070Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan and pembrolizumab in triple-negative breast cancer (TNBC) (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Aug 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON61070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61070.